Replication of the Human Secretory Pathway in Yeast

Information

  • Research Project
  • 6791073
  • ApplicationId
    6791073
  • Core Project Number
    R43GM071310
  • Full Project Number
    1R43GM071310-01
  • Serial Number
    71310
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/20/2004 - 21 years ago
  • Project End Date
    10/19/2004 - 20 years ago
  • Program Officer Name
    MARINO, PAMELA
  • Budget Start Date
    4/20/2004 - 21 years ago
  • Budget End Date
    10/19/2004 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/19/2004 - 21 years ago
Organizations

Replication of the Human Secretory Pathway in Yeast

DESCRIPTION (provided by applicant): Although Pichia pastoris is known for its ability to secrete high levels of recombinant proteins, actual yields vary widely for individual proteins. Consequently, GlycoFi's longterm objectives are focused on the improvement of protein yields in P. pastoris as part of the company's mission to develop yeast and fungi-based platforms for the production of therapeutic proteins with human glycosylation structures. The goal of this Phase I project is to develop and test a strategy for overcoming bottlenecks in the secretory process causing less than optimal yields, focusing specifically on improving translocation of the nascent peptide into the endoplasmic reticulum (ER) and protein folding within the ER. The project aims are to 1) assemble a library of fungal signal sequences, 2) create a library of human chaperone proteins, and 3) develop a screening method to test these signal sequences and chaperone proteins for increased secretion of a model protein. Taken together, Phase I aims will result in the creation of a toolkit for producing a more human-like secretory pathway in yeast strains expressing a recombinant protein. The toolkit will be utilized in Phase II in a high throughput screen to identify combinations of signal sequences and chaperones that optimize yield. Proposed Commercial Application: With a worldwide lack of manufacturing capacity blocking the development pipeline for new therapeutics, GlycoFi's technology will provide the biopharmaceutical industry with a high capacity alternative to mammalian cell culture that will allow life-improving drugs to reach the clinic in a faster, more cost-effective manner.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GLYCOFI, INC.
  • Organization Department
  • Organization DUNS
    928700132
  • Organization City
    LEBANON
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    03766
  • Organization District
    UNITED STATES